post stroke clinical trials results

anticoagulant versus no anticoagulant
Baker, 1964	unnamed anticoagulant (TQ (2 to 2.5 times control in seconds), started in hospital versus no treatment		open
Bradshaw, 1975	warfarin or phenindione for 18 mo; TP time 2x control versus no treatment		open UK
LHSPS, 1999	unfractionated heparin 12.500 IU/d plus ’usual therapy’ versus usual therapy		open Follow-up duration: 2 years Italy
VA Study, 1961	coumadin or dicumarol, prothrombin activity 20% of normal versus no treatment		open Follow-up duration: 11 months USA
Wallace, 1964	phenindione or warfarin, Quick test 20% to 35% of normal (50% after 10 months) versus no treatment		open Follow-up duration: 9.75 months Australia
anticoagulant versus placebo
McDevitt, 1959	dicumarol or warfarin, Quisk test 2 to 2.5 times control in seconds versus placebo		single-blind Follow-up duration: 34 months USA
aspirin versus placebo
Canadian study (CCSG), 1978	aspirin 325 mg/d versus placebo		Double blind Follow-up duration: ND
Swedish study , 1987	aspirin 1,500 mg/d versus placebo		Follow-up duration: 2 y
UK-TIA low dose , 1988	aspirin 300 mg/d versus placebo		Follow-up duration: 4 y
UK-TIA high dose , 1988	aspirin 1,200 mg/d versus placebo		Follow-up duration: 2y
SALT , 1991	aspirin 75 mg/d versus placebo		Follow-up duration: 32 mo
Reuther , 1976	aspirin 1,500 mg/d versus placebo		Follow-up duration: 2 y
AITA, 1975	aspirin 1,300 mg/d versus placebo		Follow-up duration: 1 y
DCS, 1980	aspirin 1,000 mg/d versus placebo		Follow-up duration: 25 mo
AICLA, 1981	aspirin 990 mg/d versus placebo		Follow-up duration: 3 y
Lindblad , 1991	aspirin 75 mg/d, during 6 months versus placebo		Follow-up duration: 6 mo
Danish low-dose, 1986	aspirin 50-100 mg/d (mean 54 mg/d) versus placebo		Follow-up duration: 23 mo
ESPS 2 , 1996	aspirin 50 mg/d versus placebo		Follow-up duration: 2 y
atorvastatin versus placebo
SPARCL, 2006 NCT00147602	atorvastatin 80mg daily versus placebo	patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 2.6 to 4.9 mmol per liter, and had no known coronary heart disease	double blind Follow-up duration: 4.9y (median)
dicoumarol versus placebo
Howard, 1963	dicumarol, TP 15 to 25% of normal versus placebo		single-blind Follow-up duration: 1 year USA
Nat-Coop, 1962	heparin 50 mg 4-hourly iv then dicumarol, Quick test 15% to 25% of control versus placebo		single-blind Follow-up duration: 13 months USA
folic acid, vit B12 and vit B6 versus placebo
VITATOPS, 2010 NCT00097669ÐX&	folic acid and vitamins B12 and B6 in a single tablet versus placebo	patients with recent stroke or TIA (within the past seven months)	double-blind Follow-up duration: 3.4 y 20 countries
high dose - folic acid, vit B12 and vit B6 versus low dose - folic acid, vit B12 and vit B6
VISP (Toole), 2004	high-dose of folic acid, pyridoxine (vitamin B6), and cobalamin (vitamin B12) versus low-dose of folic acid, pyridoxine (vitamin B6), and cobalamin (vitamin B12)	adults with nondisabling cerebral infarction	double blind Follow-up duration: 2 y United States, Canada, Scotland
phenindione versus placebo
Enger, 1965	phenindione thrombotest 10% to 25% of normal, started in hospital versus placebo		single-blind Follow-up duration: 22.7 months Norway
Thygesen, 1964	phenindione, prothrombin-proconvertin test 10% to 20% versus placebo		single-blind Follow-up duration: 29.5 months Denmark
rivaroxaban versus aspirin
NAVIGATE ESUS, 2018 NCT02313909	rivaroxaban (at a daily dose of 15 mg) versus aspirin (at a daily dose of 100 mg)	patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source
simvastatin versus placebo
HPS (post troke sub group), 2004	simvastatin 40mg daily versus placebo	adults with cerebrovascular disease, total cholesterol >=3·5 mmol/L and without coronaro disease (n=1820)	double blind
Starflex versus medical treatment
CLOSURE I, 2010 NCT00201461	patent foramen ovale closure using the Starflex device versus best medical therapy: aspirin (325 mg daily) and/or warfarin (target INR = 2.5)	patients with a stroke and/or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale	open Follow-up duration: 2 years US, Canada
telmisartan versus placebo
PROFESS, 2008	telmisartan 80 mg/d versus placebo
warfarin versus aspirin
SWAT, 1998	warfarin (INR 2.0 to 3.0) versus Enteric-coated aspirin 650 mg 12-hourly		open Follow-up duration: 2 years USA